|
Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia |
Dec 2020 |
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Aplastic Anemia |
|
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients |
Jul 2020 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria |
Jan 2021 |
Leukemia |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes |
Aug 2020 |
Nature Medicine |
Myelodysplastic Syndromes (MDS) |
|
In Search for a Haemoglobin Threshold in Myelodysplastic Syndromes |
Jun 2020 |
British Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
|
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria |
Jun 2023 |
Blood |
Aplastic Anemia |
|
Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria |
Jun 2024 |
Journal of Managed Care & Specialty Pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes |
Oct 2020 |
Annals of internal medicine |
Myelodysplastic Syndromes (MDS) |
|
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria |
Apr 2021 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
